

Seikagaku Announces Revision of Forecast of Full-Year Consolidated Financial Results for the Fiscal Year Ending March 31, 2021

Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announced today that it has revised the forecast of full-year consolidated financial results for the fiscal year ending March 31, 2021 (fiscal 2020) disclosed on September 24, 2020, follows based on results of operations thus far in the fiscal year.

1. Revision of forecast of full-year consolidated financial results for fiscal 2020 (April 1, 2020 to March 31, 2021)

(Millions of yen)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of parent	Net income per share (Yen)
Previous forecast (A)	26,650	550	1,400	1,150	20.38
Revised forecast (B)	27,500	850	2,050	1,700	30.13
Change (B-A)	850	300	650	550	—
Change (%)	3.2	54.5	46.4	47.8	—
Reference: Results for fiscal 2019	28,642	1,960	3,981	(10,839)	(192.15)

2. Reason for the revision

Net sales are expected to exceed the previous forecast, reflecting softer-than-expected-impact of COVID-19 on sales of overseas pharmaceuticals and overseas sales in the LAL business.

As for the earnings outlook, operating income is expected to exceed the previous forecast, with a projected increase in net sales compared to the previous forecast compensating for higher R&D expenses.

Ordinary income and net income attributable to owners of parent are also expected to exceed the previous forecasts, reflecting a projected increase in royalty income related to overseas products.

Seikagaku forecasts R&D expenses of ¥7,700 million (¥300 million above the previous forecast of ¥7,400 million).

Note: The above forecast has been prepared on the basis of economic circumstances, market trends, and other assumptions made at the time of release of this document. Actual results may differ from the forecast due to a variety of factors.

#####